Pittsburgh-based MetasTx, LLC is developing a precision-oncology platform that pairs a diagnostic for identifying prostate cancer patients at high risk of metastasis with next-generation KIT inhibitors intended to block cancer spread and treatment resistance. Its NCI-supported diagnostic study with Allegheny Health Network and licensed inhibitor compounds from the Crich UGARF laboratories connect clinical research with a targeted therapeutic program. The company’s leadership brings experience from institutions and oncology organizations including Merck and AstraZeneca.
National Cancer Institute Funding
Compliance program
Predictive OncologyPittsburgh-based Predictive Oncology uses machine learning, human tumor data and laboratory models to support oncology drug discovery and clinical treatment decisions. Its proprietary platform draws on a privately held biobank of more than 150,000 tumor samples, while its CLIA-certified Helomics laboratory provides tumor drug-response and genomic testing alongside research support for biopharmaceutical developers.PITTSBURGH, PA
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV
Zetagen TherapeuticsFounded in 2015, Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company built around a patient-centered approach to cancer research. From its Colleen Connor Cancer Research Lab, the company develops local treatments for people with metastatic cancer affecting bone, including the investigational therapy ZetaMet, which is designed to address tumors while supporting bone repair.SYRACUSE, NY
Creatv BioPrivately held Creatv MicroTech, led by MIT-trained scientist and founder Cha-Mei Tang, is known for bringing diagnostics together with microfabrication to develop cancer research technologies. Its Creatv Bio division applies that expertise to blood-based liquid-biopsy research for cancer screening and treatment monitoring, including work with biopharma companies and clinical-trial sponsors. Creatv MicroTech received an R&D 100 Award in 2006 and was named Montgomery County’s Biotech Company of the Year in 2013.POTOMAC, MD